Co-diagnostics jv cosara receives clearance from indian fda for chikungunya and dengue tests

Salt lake city, sept. 16, 2021 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that cosara diagnostics pvt ltd ("cosara," or the "jv"), its joint venture for manufacturing and sales in india, has received clearance by the central drugs standard control organization ("cdsco") in india to manufacture and sell its saragene™ dengue and chikungunya rt-pcr tests as in vitro diagnostics ("ivd").
CODX Ratings Summary
CODX Quant Ranking